CSS
ANTX icon

Cubist Systematic Strategies’s AN2 Therapeutics ANTX Stock Holding History

Cubist Systematic Strategies’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,825
Closed -$27.6K – 2953
2024
Q2 		$27.6K Buy
+12,825
New +$30.5K ﹤0.01% 2754
2024
Q1 		– Sell
-16,483
Closed -$338K – 3674
2023
Q4 		$338K Buy
+16,483
New +$276K ﹤0.01% 2735

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's ANTX Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 12,825 shares — an estimated $27.6K sold.

Cubist Systematic Strategies first reported a position in ANTX in Q4 2023 and held it in 2 quarters. The position peaked at $338K in Q4 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 12,825 AN2 Therapeutics shares in Q3 2024, an estimated $27.6K.
  • Cubist Systematic Strategies first reported a position in AN2 Therapeutics in Q4 2023 and held it in 2 quarters.
  • Cubist Systematic Strategies's AN2 Therapeutics position peaked at $338K in Q4 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.